Vol 6, No 4 (2021)
Original article
Published online: 2021-12-30

open access

Page views 5685
Article views/downloads 335
Get Citation

Connect on Social Media

Connect on Social Media

Renal impairment in patients admitted due to COVID-19 — the experience of University Hospital No 1 in Bydgoszcz

Małgorzata Jasiewicz1, Klaudyna Grzelakowska2, Agata Sobacka2, Michał Kasprzak1, Jacek Kryś3, Jacek Kubica1
Medical Research Journal 2021;6(4):330-333.

Abstract

Introduction: COVID-19 is a prominently respiratory infection, with potential renal complications. Our objective was to describe the incidence of renal impairment and its influence on clinical outcome in patients admitted to University Hospital No 1 in Bydgoszcz due to COVID-19.
Material and methods: In this single-center observational study we retrospectively identified patients
with a positive test result for SARS-CoV-2 from either a nasopharyngeal or oropharyngeal swab PCR (n = 988) who were admitted to University Hospital No 1 in Bydgoszcz, Poland since April 1, 2020 to April 30, 2021. Details of the patients’ demographics, diagnoses (based on ICD-10 codes), eGFR and clinical outcomes were obtained using a combination of a manual chart review of the electronic medical record from the hospital database.
Results: Median baseline eGFR was 77,4 ml/min (IQR 51,6–93,7 ml/min) and minimal eGFR was 68,7 ml/min (IQR 39,9–90 ml/min), p < 0,05. We found significant differences in median baseline and minimal eGFR between patients discharged and deceased (80,8 vs. 55,4 ml/min and 73,7 vs. 33 ml/min, respectively, p < 0,001). Patients who died (12,5 %) were older, with more co-morbidities including CKD and AKI, and presented a significantly lower value of eGFR both at baseline and during hospital stay, as well as, more frequent and extensive deterioration of eGFR. Factors predisposing to in-hospital death were age, atrial fibrillation, heart failure, coronary artery disease, and among them AKI and CKD were strong negative prognostic parameters.
Conclusions: Renal impairment on admission as well as during hospitalization among patients with SARS-CoV-2 infection is a risk factor of negative outcome.

Article available in PDF format

View PDF Download PDF file

References

  1. Boraschi P. COVID-19 Pulmonary Involvement: Is Really an Interstitial Pneumonia? Acad Radiol. 2020; 27(6): 900.
  2. Hirsch J, Ng J, Ross D, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney International. 2020; 98(1): 209–218.
  3. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020; 97(5): 829–838.
  4. Perico L, Benigni A, Remuzzi G, et al. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Nephron. 2020; 144(5): 213–221.
  5. Batlle D, Soler MJ, Sparks MA, et al. COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. J Am Soc Nephrol. 2020; 31(7): 1380–1383.
  6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239–1242.
  7. Richardson S, Hirsch JS, Narasimhan M, et al. the Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020; 323(20): 2052–2059.
  8. Hansrivijit P, Qian C, Boonpheng B, et al. Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis. J Investig Med. 2020; 68(7): 1261–1270.
  9. Zhang G, Hu C, Luo L, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020; 127: 104364.
  10. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020; 52(6): 1193–1194.
  11. Betjes M. Immune cell dysfunction and inflammation in end-stage renal disease. Nature Reviews Nephrology. 2013; 9(5): 255–265.
  12. Aly MH, Rahman SS, Ahmed WA, et al. Indicators of Critical Illness and Predictors of Mortality in COVID-19 Patients. Infect Drug Resist. 2020; 13: 1995–2000.
  13. Ielapi N, Licastro N, Provenzano M, et al. Cardiovascular disease as a biomarker for an increased risk of COVID-19 infection and related poor prognosis. Biomark Med. 2020; 14(9): 713–716.